The Antimicrobial Resistance (AMR) contributes to more than 700,000 deaths annually and considered a major global health catastrophe. Due to the ineffectiveness of the majority of the existing drugs against multidrug-resistant (MDR)strains of bacteria and fungi, there is an unmet need for newer potent antimicrobials. The PeptomerTherapeutics has invented novel platforms that help to develop a range of antimicrobial peptides and oligomers. We are based at the BSC BioNEST Bio-Incubator, Regional Centre for Biotechnology (RCB), Faridabad.
|Dr Kantaraja Chindera||Dr Ravindra P Veeranna||Princy||Yash Ranga|
|Director and Co-founder||Co-founder||Senior Scientist||Formulation Chemist Scientist|
|Research Scientist||Research Scientist||Lab Technician|
|Deepika Chaudhary||Anshul||Anjali Pandey|
|Research Scientist||Research Scientist||Research Scientist|